These results identified that TGM3 may serve as a marker of malignancy risk and clinical prognosis as well as an indicator of immunotherapy response and a potential target for cancer therapy, especially in some poorly curative or highly drug-resistant tumors. This evidence concerns the gene TGM3 and cancer.